|
Gene: IGSF11 |
Gene summary for IGSF11 |
Gene summary. |
Gene information | Species | Human | Gene symbol | IGSF11 | Gene ID | 152404 |
Gene name | immunoglobulin superfamily member 11 | |
Gene Alias | BT-IgSF | |
Cytomap | 3q13.32 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q5DX21 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
152404 | IGSF11 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.17e-02 | 6.69e-01 | -0.2602 |
152404 | IGSF11 | HTA11_83_2000001011 | Human | Colorectum | SER | 3.26e-04 | 3.87e-01 | -0.1526 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00451851 | Colorectum | SER | maintenance of protein location | 26/2897 | 94/18723 | 1.76e-03 | 1.81e-02 | 26 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IGSF11 | SNV | Missense_Mutation | novel | c.1155N>A | p.Met385Ile | p.M385I | Q5DX21 | protein_coding | tolerated(0.12) | benign(0) | TCGA-53-A4EZ-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
IGSF11 | SNV | Missense_Mutation | c.180N>T | p.Met60Ile | p.M60I | Q5DX21 | protein_coding | tolerated(0.07) | possibly_damaging(0.874) | TCGA-55-8094-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
IGSF11 | SNV | Missense_Mutation | c.337T>A | p.Ser113Thr | p.S113T | Q5DX21 | protein_coding | tolerated(0.14) | benign(0.111) | TCGA-73-4670-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | SD | |
IGSF11 | SNV | Missense_Mutation | c.1228A>T | p.Thr410Ser | p.T410S | Q5DX21 | protein_coding | deleterious(0.02) | benign(0.193) | TCGA-78-7154-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
IGSF11 | SNV | Missense_Mutation | c.1058N>T | p.Asn353Ile | p.N353I | Q5DX21 | protein_coding | tolerated(0.12) | benign(0) | TCGA-L9-A8F4-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
IGSF11 | SNV | Missense_Mutation | novel | c.344N>A | p.Thr115Asn | p.T115N | Q5DX21 | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-MP-A4T4-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGSF11 | SNV | Missense_Mutation | novel | c.934N>C | p.Thr312Pro | p.T312P | Q5DX21 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
IGSF11 | SNV | Missense_Mutation | c.194N>T | p.Ser65Phe | p.S65F | Q5DX21 | protein_coding | deleterious(0) | possibly_damaging(0.828) | TCGA-18-3409-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
IGSF11 | SNV | Missense_Mutation | c.938N>T | p.Ser313Phe | p.S313F | Q5DX21 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-21-1070-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
IGSF11 | SNV | Missense_Mutation | c.653N>G | p.Ser218Cys | p.S218C | Q5DX21 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-21-1071-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |